258 results about "Nasopharyngeal cancer" patented technology

The invention discloses a nasopharyngeal carcinoma radiotherapy target region automatic segmentation method based on a deep neural network, and belongs to the field of nasopharyngeal carcinoma radiotherapy target region automatic segmentation. The method comprises the following steps: acquiring CT image data of a patient, sketching a nasopharyngeal carcinoma radiotherapy target region and endangering organs based on the CT image data, and dividing the sketched CT image data into a training set and a verification set; constructing a deep neural network segmentation model, preprocessing trainingsamples in the training set, using the preprocessed training samples for training the deep neural network segmentation model, wherein preprocessing comprises the steps of reducing the numerical rangeof the training samples to a specified range and augmenting the training samples; and reducing the numerical range of the training samples in the verification set to a specified range, inputting thenumerical range into the trained deep neural network segmentation model, and quantitatively evaluating the recognition effect of the model. According to the invention, the model can automatically output the segmentation result of the nasopharyngeal carcinoma radiotherapy target area and organs endangering the nasopharyngeal carcinoma radiotherapy target area in a short time only by inputting the CT image data of the patient.

The invention relates to an auxiliary assessment method for prognosis of nasopharynx cancer based on enhanced MRI radiomics. The auxiliary assessment method comprises the steps of: (1), performing MRIimage processing; (2), extracting imaging features; (3), screening the imaging features; (4), establishing a radiomics scoring formula; (5), screening clinical risk factors; and (6), establishing a prognostic survival model: establishing a prognostic observation model through combination of a radiomics score and the clinical risk factors of a patient with nasopharynx cancer, performing qualitative and quantitative prediction on the PFS (progression free survival) of the patient, and furthermore, assessing the performance of the prognostic survival model. The auxiliary assessment method in theinvention has little harm to the image examination of the patient; qualitative and quantitative analysis on the survival time of a specific patient is carried out; therefore, a doctor is assisted tomake an individualized treatment and follow-up visit scheme; furthermore, the doctor is assisted to assess the survival and recurrence time of the patient; simultaneously, the performance of the obtained prognostic survival model is verified; and thus, the accuracy of a prognostic prediction model is ensured.

The invention pertains to the field of traditional Chinese medicine for treating tumors and provides a traditional Chinese medicine for treating nasopharyngeal cancer, which is characterized by good curative effect and high efficiency. The traditional Chinese medicine for treating nasopharyngeal cancer is prepared from traditional Chinese medicinal materials including faeces trogopterorum, lacca sinica exsiccate, panax pseudoginseng, selaginella doederleinii hieron, glossy ganoderma, radix sophorae tonkinensis, angelica, rhizoma bolbostemmae, scolopendra and the like, can strengthen the body resistance and consolidate the constitution, benefit Qi and nourish the blood, promote blood circulation to remove blood stasis, clear away heat and toxic materials and fight against cancer, and has the advantages of good curative effect, high efficiency and remarkable result.

The invention discloses an S-(5-substituted-1, 3, 4-thiadiazole)-(5-substituted phenyl)-2-furancarbothioic acid ester compound, a preparation method and application thereof. The compound has a structural general formula shown as formula I. The S-(5-substituted-1, 3, 4-thiadiazole)-(5-substituted phenyl)-2-furancarbothioic acid ester compound has an obvious control effect on potato late blight, cucumber fusarium wilt, Botrytis cinerea Pers, Pepper Phytophthora blight, rice sheath blight, wheat scab, Colletotrichum musae, asparagus stem blight and the like, and can be used as an agricultural fungicide in control of plant diseases. At the same time, the compound has an inhibitory effect on HL-60 human leukemia cells, MCF-7 human breast cancer cells, BGC-823 human gastric cancer cells, Bel-7402 human hepatocellular carcinoma cells, and KB human nasopharyngeal carcinoma cells, etc., and has application prospects in the aspect of anti-tumor activity. (formula I).

The invention discloses tetrahydropalmatine derivatives and a preparation method and application thereof. The structural formula of the tetrahydropalmatine derivatives is shown as a formula II, wherein R is octyl, isopropyl or 3-methybutyl. The provided application is the application of the tetrahydropalmatine derivatives shown as the formula II or pharmaceutically acceptable salts thereof in the preparation of eukaryotic tumor cell antiblastics and medicaments for preventing and / or treating tumors. The results of in-vitro anti-tumor activity experiments prove that each tetrahydropalmatine derivative has the effect of inhibiting human lung cancer cells A-549, KB human nasopharyngeal carcinoma cells, and HL-60 leukemia cell strains to a certain extent. The results show that the tetrahydropalmatine derivatives shown as the formula II can be applied to preparing the medicaments for treating the tumors, and the pharmaceutical application of the tetrahydropalmatine derivatives is widened.

The invention relates to an automatic design method for a nasopharyngeal carcinoma radiotherapy plan based on machine learning, and provides a method for searching for a patient optimal objective function based on Overlap Volume Histogram (OVH) data and in combination with machine learning nearest neighbor method. The method comprises establishing a template library by using existing data, searching for the most similar cases in the OVH data and the template library of newly enrolled patients by using the machine learning nearest neighbor method, and planning the radiotherapy plan of the newlyenrolled cases by using the objective function of the searched radiotherapy plan of the newly enrolled cases. The case template is searched without the need for human subjective factors, and the patient's nasopharyngeal carcinoma radiotherapy plan is automatically designed.

The invention discloses an oral Chinese herbal compound for treating nasopharyngeal darcinoma, belonging to the Chinese traditional medicine. The oral Chinese herbal compound for treating nasopharyngeal darcinoma is prepared with the following weights of raw materials: 40g of gypsum, 6g of processed rhubarb, 5g of szechwan lovage rhizome, 4g of cicada slough, 30g of radix rehmanniae, 30g of figwort, 10g of cortex moutan, 10g of licorice products, 10g of honeysuckle, 20g of prunella vulgaris and 6g of liquorice. The herbs are decocted in water for oral taking; one dose of the decoction is taken in one day; each dose is decocted for two times and separated for taking in the morning and in the evening. The oral Chinese herbal compound for treating nasopharyngeal is reasonable in prescription, convenient in preparation, used for remedying incomplete treatment to the nasopharyngeal and various side effects by radiochemotheraphy, and evident for the treatment effect.

The invention discloses an application of 3,5-(E)-diarylmethylene-N-cyclopropyl piperidin-4-one compounds as an Hsp90 depressant. The invention discloses use of the 3,5-(E)-diarylmethylene-N-cyclopropyl piperidin-4-one compounds 1-4 represented by formulae shown in the description and compositions thereof in preparation of drugs for treating or preventing Hsp90 induced diseases. According to the use disclosed by the invention, the Hsp90 induced diseases are leukemia, colon cancer, liver cancer, lymphoma, nasopharyngeal carcinoma or breast cancer. According to the application, the compounds have powerful Hsp90 depression activity, and in vitro, the depression activity of the compounds 1-4 to six kinds of tumor cells is higher than that of 2F by 2 to 20 times. In vivo, relatively high nude-mouse transplantation tumor propagation depression activity is shown, so that the compounds can be used for preparing drugs for treating the leukemia, the colon cancer, the liver cancer, the lymphoma, the nasopharyngeal carcinoma and the breast cancer.

The present invention discloses a cyclic pentapeptide with anti-tumour activity, which is cyclic (leucyl-N-methylleucyl-leucyl-leucyl-N-methylleucyl) and the constitutional formula of which is shown in the formula (I). The cyclic pentapeptide of the present invention is separated from galaxaura filamentosa in the South China Sea, and in vitro experiments show that the cyclic pentapeptide has strong inhibiting effect on human hepatoma cell lines (HepG2), human hepatoma cell lines (BEL-7402), human mammary cancer cell lines (MCF-7), human colon cancer cell lines (LOVO), human lung cancer cell lines (PC84045) and human nasopharyngeal cancer (CNE) and can keep the mitotic cycle of BEL-7402 hepatoma cells in G2 / M phase. The present invention provides a pilot compound for the research and the development of new anti-tumour drugs and is valuable for the exploitation of the marine pharmaceutical resources of China.

The invention discloses a tumor microenvironment component marker combination and system for predicting nasopharyngeal carcinoma prognosis. The tumor microenvironment component marker combination comprises a cell cycle proliferation component and at least one of five immune cell components including macrophages, plasmacytoid dendritic cells, CLEC9A + dendritic cells, natural killer cells and plasma cells. According to some examples of the invention, the expression levels of different components in a nasopharyngeal carcinoma tumor microenvironment can be predicted by calculating the expressionlevels of respective feature genes of one tumor cell component and five immunocyte components, and clinical prognosis prediction can be performed on a nasopharyngeal carcinoma patient, so that individualized treatment is facilitated, and finally, survival benefits are brought to the patient.

The invention provides a method for preparing gynecological menstruation regulating tablets. The menstruation regulating tablets are prepared from 144g of Chinese angelica, 16g of Szechuan lovage rhizome, 400g of vinegar baked rhizoma cyperi, 23g of bran baked bighead atractylodes rhizome, 12g of white peony root, 12g of red peony root, 32g of vinegar baked corydalis tuber, 48g of prepared rehmannia root, 80g of jujube and 11g of licorice serving as raw medicaments by adopting supercritical extraction and microwave extraction, so that the ferulic acid content is greatly improved. The invention also provides application of the gynecological menstruation regulating tablets in preparation of a medicament for inhibiting propagation of human nasopharyngeal carcinoma CNE-2Z cells.

The invention provides an anticancer traditional Chinese medicine composition, belonging to the technical field of medicines. The traditional Chinese medicine composition comprises bezoar, sweet wormwood herb, musk, root of China creeper and all-grass of nerved twayblade. The traditional Chinese medicine composition has the beneficial effects that through a reasonable ratio of the five medicinal raw materials, the traditional Chinese medicine composition has synergetic effects and the double effects of directly inhibiting cancer cell growth and proliferation and enhancing the immune function; through clinical research trials, the traditional Chinese medicine composition can selectively inhibit and kill cancer cell proliferation to achieve the anticancer effect, can also promote differentiation of T and B lymphocytes and activate NK cells to enhance the body immunity, has quick treatment effects on cancers, does not have toxic or side effect, has a wide anticancer spectrum, especially has obvious curative effects on lung cancers, liver cancers, gastric cancers, intestinal cancers, lymph cancers, brain tumors, nasopharynx cancers, esophagus cancers, pancreatic cancers and cervical cancers, and does not have any impact on body cells, tissues, organ functions and hemogram in the medication period.

The invention provides a method for establishing a human nasopharyngeal carcinoma tumor stem cell line. The method comprises the following steps: (1) obtaining human nasopharyngeal carcinoma cells in the single cell state; (2) adding the human nasopharyngeal carcinoma cells in the single cell state, obtained in the step (1), to a serum-free stem cell culture medium containing epidermal growth factors and basic fibroblast growth factors to obtain single cell suspension; (3) adjusting the concentration of the single cell suspension in the step (2) to 900-1100 single cells / ml; (4) inoculating 1ml of the single cell suspension obtained in the step (3) into single pores on a cell culture six-pore plate and then adding the equivoluminal stem cell culture medium for culture for 72-96 hours; and (5) collecting the cells obtained in the step (4), carrying out trypsinization till the single cell and carrying out subculture. The method provided by the invention is simple and convenient to operate; and the obtained nasopharyngeal carcinoma stem cell line has obvious stem cell characteristics.

The invention discloses a method for screening nasopharyngeal carcinoma radiotherapy resistant cells by using a radioactive irradiation mode. The method adopts a screening mode of radioactive gradient increasing. By adopting the method, cells can adapt to high-dose radioactive irradiation more rapidly within a relatively short time, the time of growth recovery after single high-dose radioactive irradiation can be shortened, the possibility of generating radiotherapy resistance can be increased, and meanwhile, the investment of manpower, material resources and time can be reduced. The constructed nasopharyngeal carcinoma radiotherapy resistant cells are used for providing a good cell model for the study on nasopharyngeal carcinoma radiotherapy resistance. The method disclosed by the invention is suitable for nasopharyngeal carcinoma cell strains cultured in vitro, and also can be used for providing references for the establishment of other tumor radiotherapy resistant cells.

The present invention relates to 2′-Fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and / or adefovir resistant) and other mutant forms of these viruses, especially HBV.

The invention discloses an NPC (nasopharyngeal carcinoma) related tumor marker and an application. The tumor marker is lncRNA, is positioned at the 17th chromosome chr17:47785696-47797422 and has the nucleotide sequence shown in SEQ ID NO.1 and named as lncRNA-KAT7. According to the sequence lncRNA-KAT7, the specific real-time fluorescent quantitative PCR primer is designed and synthesized, and a preparation used for NPC diagnosis or curative effect prediction is prepared. Detection of the expression level of lncRNA-KAT7 in an NPC clinical case specimen by use of the real-time fluorescent quantitative PCR preparation proves that expression of lncRNA-KAT7 in NPC is remarkably reduced, and lncRNA-KAT7 can be used for preparing a preparation or a kit for auxiliary diagnosis, curative effect prediction and prognosis of NPC.

The invention discloses a molecular target hsa-miR203 for diagnosing and treating nasopharyngeal cancer related with Epstein-Barr virus (EBV) infection and application thereof. The microRNA can accurately reflect the conditions of retention and loss of EBV viruses in cells and tissues, and further can be used for diagnosing the nasopharyngeal cancer related with the EBV infection; and meanwhile, target genes E2F3, CCNG1 and the like controlled by the hsa-miR203 obviously inhibit the proliferation and conversion capacities of the cells, so the hsa-miR203 can be used for treating the nasopharyngeal cancer related with the EBV infection. Therefore, the hsa-miR203 has important scientific research theory and clinical application value, and provides new clue and proof for diagnosis, treatment or prognosis of EBV related tumors.

The invention provides an application of a YH1 protein to combination and agglutination of pathogenic microorganisms, provides an application of the YH1 protein to preparation of a medicament for treating inflammation-relevant diseases caused by bacterial infection, and discloses a preparation method of the YH1 protein. The method comprises the following steps of: constructing an expression vector; constructing expression engineering bacteria; and performing induced expression, purification and enzyme digestion. A recombinant YH1 protein obtained with the method has bioactivity. According to the recombinant YH1 protein, pathogenic microorganisms can be combined and agglutinated, so that the YH1 protein plays a role in killing gram negative bacteria, and can be used for preventing and treating inflammation caused by bacterial infection.

The invention discloses the application of human lactoferrin (hLTF) and its ELISA detection kit in diagnosis of nasopharyngeal carcinoma. The invention proves the specific down-regulation of hLTF gene in nasopharyngeal carcinoma tissue by experiments so as to provide the use of hLTF in diagnosis, screening and prognosis of nasopharyngeal carcinoma. The invention further provides an anti-hLTF antibody and an hLTF ELISA detection kit for diagnosis of nasopharyngeal carcinoma by double-antibody sandwich method. The expression level of LTF in nasopharyngeal secretion from different people can be quantitatively detected by collecting secretion from nasopharynx with ELISA method, so as to predict the risk of nasopharyngeal carcinoma, screen susceptible persons, and perform early and rapid non-invasive diagnosis to nasopharyngeal carcinoma patients.

The invention provides application of periplaneta americana powder or a periplaneta americana extract in preparation of a drug for preventing and treating radiation-induced damage. The drug is used for preventing and treating damage caused by radiotherapy conducted on a nasopharynx cancer, an esophagus cancer, an esophageal cancer, a gastric cancer, a lung cancer, a liver cancer, a breast cancer, Webster's lymphoma and other cancers, and especially has the obvious effect of preventing and treating the damage caused by the radiotherapy to patients suffering from the breast cancer. It is found through research that the drugs can effectively prevent radioactive skin damage to mice.

The invention discloses a glaucocalyxin A derivative, a preparation method and application thereof. The glaucocalyxin A (GLA) is used as a main body of the glaucocalyxin A (GLA) derivative which is a diterpenes substance and has an ent-kaurane structure, carbonyl, polypeptide cNGQGEQc and / or hydroxyl. In the invention, rabdosia amethystoides medicinal material (part on the above-ground) is used as a raw material, and the preparation method of the derivative is as follows: crashing the raw material, extracting, treating solution, passing through a column, recrystallizing and carrying out other steps to obtain the glaucocalyxin A (GLA), and further carrying out acetylation on the glaucocalyxin A (GLA) and the polypeptide cNGQGEQc to obtain the glaucocalyxin A (GLA) derivative. The glaucocalyxin A (GLA) derivative has high anticancer activity, can significantly inhibit a plurality of tumor cells such as cells in lung cancer, liver cancer, nasopharyngeal carcinoma, lymphoma, melanoma and myelomatosis, especially has a targeting effect on the lung caner and can pertinently treat the lung caner.

The present invention relates to cancer and in particular to oral and nasopharyngeal cancers. In particular, the present invention relates to a method of detection and diagnosis of oral squamous cell carcinoma (OSCC) and nasopharyngeal cancers by determining the expression levels of certain genes. The method comprising (a) determining in a biological sample from the patient the amount of the expression level of at least one gene selected from the group consisting of GNA-12 and IFITM3; and (b) comparing the determined expression levels of said genes in said biological sample with the level in a reference. The invention also relates to polypeptides, antibodies and nucleic acids of the invention for use in medicine and a kit for performing the invention.

The invention relates to an endoscopic ultrasonic imaging device and an endoscopic ultrasonic imaging method for nasopharynx cancer. The device comprises a camera, a video signal processing unit, a control and imaging unit, an ultrasonic excitation and receiving unit and an ultrasonic transducer, wherein the camera is used for acquiring an optical tissue image on the inner surface of a nasopharynx; the video signal processing unit is used for converting an optical tissue image signal into a video digital signal; the control and imaging unit is used for storing and displaying the digital signal and sending a control instruction; the ultrasonic excitation and receiving unit is used for generating a specific pulse signal according to an ultrasonic control instruction for ultrasonic excitation, processing an ultrasonic echo signal and then performing ultrasonic image display; the ultrasonic transducer is used for generating an ultrasonic wave for scanning the interior of the nasopharynx according to the pulse signal, receiving the ultrasonic echo signal and converting the ultrasonic echo signal into an electric echo signal; the ultrasonic excitation and receiving unit is also used for processing the electric echo signal; the control and imaging unit is also used for performing ultrasonic imaging according to the processed electric echo signal. The detection accuracy is improved.

The invention relates to a traditional Chinese medicine composition for treating cancers, which contains three active components, including chan garment, acanthopanax and tolypocladium sinensis mycelia, wherein the cancers include solid tumor, preferably liver cancer, lung cancer, breast cancer, esophagus cancer, stomach cancer, nasopharyngeal cancer, ovarian cancer, bladder cancer, rectal cancer,skin cancer and lymphoma, and further preferably liver cancer; particularly, the traditional Chinese medicine composition has specially and obviously effect of treating liver cancer with cirrhosis and ascites. The chan garment, acanthopanax and tolypocladium sinensis mycelia preparation not only has amazing treating effect on tumors as diseases upsetting human beings, but also utilizes the chan garment generated by the naturally molting phenomenon of a bufonid, thereby not only effectively utilizing resources, but also protecting the ecological environment.

The invention discloses an aromatic hydrocarbon ruthenium complex and an application thereof as an antitumor drug. For the aromatic hydrocarbon ruthenium complex, methyl benzene is taken as a ligand, phenanthro-imidazole and derivatives of phenanthro-imidazole are taken as the second ligand, and a chlorine atom is taken as the third ligand. The complex can inhibit the propagation, invasion and metastasis of tumor cells, has an especially good effect on inhibiting growth of cells of breast cancer, brain glioma, leukemia, nasopharyngeal carcinoma, and pulmonary adenocarcinoma, and barely damages the normal cells of human body. The invention also discloses a preparation and applications of the aromatic hydrocarbon ruthenium complex.

The invention provides a nasopharyngeal cancer artificial intelligence auxiliary diagnosis and treatment decision terminal. The diagnosis and treatment decision terminal performs data interaction witha diagnosis and treatment decision server cluster in response to a user instruction, and provides a diagnosis decision service for a user in a visual manner; and the diagnosis and treatment decisionterminal is configured to select a first model, a second model, a third model, a fourth model, and / or a fifth model to provide a diagnosis decision service for the user. The nasopharyngeal cancer artificial intelligence auxiliary diagnosis and treatment decision terminal can provide an accurate intelligent diagnosis decision service based on artificial intelligence for the user and have broad application prospects.

The invention relates to an application of a CXCR2 inhibitor in preparation of a medicine for treating nasopharynx cancer, and belongs to the field of medicine. The invention provides an application of a CXCR2 inhibitor in preparation of a medicine for treating nasopharynx cancer or preventing nasopharynx cancer relapse, an application in preparation of a radiotherapy sensitizer for nasopharynx cancer and an application in preparation of a radiotherapy protective agent for nasopharynx cancer. The application of the invention is helpful for reducing toxic and side effects caused by clinical radiation therapy of nasopharyngeal carcinoma, improving the life quality of nasopharyngeal carcinoma patients and the curative effect of advanced nasopharyngeal carcinoma patients, and providing a new thought and strategy for comprehensive treatment of nasopharyngeal carcinoma clinically.

The present invention relates to the use of a compound of formula 3 or a salt thereof to prepare a medicament or phototherapeutic agent for treating the following diseases, including: acne; AIDS; viral hepatitis; diabetic retinopathy; SARS virus infection; coronavirus Arterial stenosis; carotid artery stenosis; intermittent claudication; Asian (chicken) avian influenza virus infection; cervical dysplasia or various cancers, including: blood cancer, cervical cancer, nasopharyngeal cancer, tracheal cancer, laryngeal cancer, bronchial cancer , bronchiolar cancer, bladder cancer, esophageal cancer, stomach cancer, rectal cancer, colon cancer, prostate cancer, hollow organ cancer, bile duct cancer, urinary tract cancer, kidney cancer, uterine cancer, vaginal cancer and other gynecological adnexal cancer. The present invention also relates to methods of treating the above diseases. The present invention further relates to the use of the compound of formula 3 or a salt thereof to prepare a photodiagnostic agent for detecting the above-mentioned diseases and the following diseases, including: atherosclerosis, multiple sclerosis, diabetes, arthritis, rheumatism Arthritis, fungal infections, viral infections, chlamydial infections, bacterial infections, or parasitic diseases, HIV viral infections, hepatitis, herpes simplex, shingles, psoriasis, cardiovascular disease, and skin diseases. The present invention also relates to methods for detecting the above diseases using photodiagnostic agents. The present invention further relates to a method for low-temperature sterilization of surgical devices or other devices, including the steps of: providing a compound of Chemical Formula 3 or a salt thereof on the device; and subjecting the device to radiation treatment or sonication treatment. The invention further relates to a compound of formula 3 or a salt thereof linked or attached to a magnetic element. This compound acts as an MRI enhancer. The invention also relates to the use of such MRI enhancers for performing MRI scans.